Hematologic Malignancies Market, By Type (Leukemia (Acute Leukemias, (Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)), Chronic Leukemias (Chronic Myeloid Leukemia (CML), Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), Others (Hairy Cell Leukemia, etc.))), Lymphoma (Hodgkin Lymphoma, Non-Hodgkin Lymphoma (NHL)), Plasma Cell Dyscrasias (Multiple Myeloma, Smoldering Multiple Myeloma, Others (Plasma Cell Leukemia, etc.)), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN), and Others (Overlap Myeloid Neoplasms (MDS/MPN), etc.)), By Age Group (Pediatric, Adult, and Geriatric), By Treatment Modality (Conventional chemotherapy (Alkylating agents, Antimetabolites, Others (Anthracyclines, etc.), Targeted therapies, (Tyrosine kinase inhibitors (e.g., BCR-ABL inhibitors), BCL-2 inhibitors, BTK inhibitors, Others (PI3K inhibitors, etc.)), Immunomodulatory drugs (IMiDs), Proteasome inhibitors, Epigenetic/differentiation agents, Monoclonal antibodies, Bispecific antibodies / T-cell engagers, and Others (Antibody-drug conjugates (ADCs), etc.)), By Route of Administration (Oral , Intravenous (IV) , Subcutaneous (SC) , and Others (Intramuscular (IM), etc.)), By Distribution Channel (Online and Offline), By End User (Hospitals , Cancer Centers , Ambulatory infusion centers , Homecare Settings , and Others (Academic and Research Institutes, etc.)), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East and Africa)